Prevention of Docetaxel- or Paclitaxel-Associated Taste Alterations in Cancer Patients with Oral Glutamine: A Randomized, Placebo-Controlled, Double-Blind Study

CME Activity Information
Release Date:	April 8, 2008
Most Recent Review:	April 8, 2008*
Most Recent Update:	April 8, 2008
Date Credit Expires:	April 8, 2010
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by April 8, 2010, in order to receive the credit or participation certificate.

1. Discuss the frequency, clinical presentation, and patient burden of taste alterations and peripheral neuropathy in patients receiving taxane-based chemotherapy.
2. Identify the risk factors for developing peripheral neuropathy and taste alterations associated with taxanes.
3. Administer glutamine treatment in the supportive care of peripheral neuropathy and taste alterations and evaluate emerging new agents.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://cme.theoncologist.com/misc/edboard.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All activity planners, authors, and reviewers are required to submit conflict of interest forms. These forms accompany the activity through the peer review process. Any reviewers who have a conflict of interest are recused. When a reviewer is recused, other suitable reviewers with no self-reported conflicts of interests are selected to conduct the reviews. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Associate Professor and Head Oncological Palliative Medicine, Division of Oncology/Haematology, Department of Internal Medicine, Cantonal Hospital, St. Gallen, Switzerland.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of glutamine, manufactured by Baxter, for the treatment of prophylaxis of taste alterations. The author has indicated no relevant commercial relationships.

Ruth Demmer

Credentials: Research Nurse, Vice-Head Trial Coordination, Division of Oncology/Haematology, Department of Internal Medicine, Cantonal Hospital, St. Gallen, Switzerland.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of glutamine, manufactured by Baxter, for the treatment of prophylaxis of taste alterations. The author has indicated no relevant commercial relationships.

Christel Böhme

Credentials: Research Nurse and Head Clinical Trial Coordination, Division of Oncology/Haematology, Department of Internal Medicine, Cantonal Hospital, St. Gallen, Switzerland.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of glutamine, manufactured by Baxter, for the treatment of prophylaxis of taste alterations. The author has indicated no relevant commercial relationships.

Shu-Fang Hsu Schmitz, Ph.D.

Credentials: Head, Statistical Unit, Swiss Group for Clinical Cancer Research, Bern, Switzerland.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of glutamine, manufactured by Baxter, for the treatment of prophylaxis of taste alterations. The author has indicated no relevant commercial relationships.

Beat Thuerlimann, M.D.

Credentials: Professor, Division of Oncology/Haematology, Department of Internal Medicine, and Senology Centre, Department of Interdisciplinary Medical Services, Cantonal Hospital, St. Gallen, Switzerland.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of glutamine, manufactured by Baxter, for the treatment of prophylaxis of taste alterations. The author has indicated no relevant commercial relationships.

Thomas Cerny, M.D.

Credentials: Professor and Director, Division of Oncology/Haematology, Department of Internal Medicine, Cantonal Hospital, St. Gallen, Switzerland.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of glutamine, manufactured by Baxter, for the treatment of prophylaxis of taste alterations. The author has indicated no relevant commercial relationships.

Silke Gillessen, M.D.

Credentials: Associate Professor and Head of Urological Oncology, Division of Oncology/Haematology, Department of Internal Medicine, Cantonal Hospital, St. Gallen, Switzerland.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of glutamine, manufactured by Baxter, for the treatment of prophylaxis of taste alterations. The author has indicated no relevant commercial relationships.

• Take this course